Statin therapy is associated with lower mortality among patients with severe heart failure

American Journal of Cardiology

Volumn 93, Issue 9, 2004, Pages 1124-1129

  Mozaffarian, Dariush ^a   Nye, Regina ^a   Levy, Wayne C ^a  

^a Building 2 ^*

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEATH; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HAZARD; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MORTALITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; AMLODIPINE; BIOLOGICAL MARKERS; CALCIUM CHANNEL BLOCKERS; CAUSE OF DEATH; CHOLESTEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STATISTICS; STROKE VOLUME; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 1942500310     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2004.01.039     Document Type: Article

References (25)

1. American Heart Association. 2002 Heart and Stroke Statistical Update. Dallas, Texas: American Heart Association; 2001
2. Health Care Financing Administration. Heart Failure National Project Overview. Available at: http://www.hcfa.gov/quality/download/3s.pdf. Accessed May 12, 2001.
3. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389.
4. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., Davis B.R., Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. CARE Trial investigators. N Engl J Med. 335:1996;1001-1009.
5. LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 339:1998;1349-1357.
6. Rauchhaus M., Coats A.J., Anker S.D. The endotoxin-lipoprotein hypothesis. Lancet. 356:2000;930-933.
7. De Pinieux G., Chariot P., Ammi-Said M., Louarn F., Lejonc J.L., Astier A., Jacotot B., Gherardi R. Lipid-lowering drugs and mitochondrial function effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol. 42:1996;333-337.
8. Marz W., Siekmeier R., Muller H.M., Wieland H., Gross W., Olbrich H.G. Effects of lovastatin and pravastatin on the survival of hamsters with inherited cardiomyopathy. J Cardiovasc Pharmacol Ther. 5:2000;275-279.
9. Ridker P.M., Rifai N., Lowenthal S.P. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation. 103:2001;1191-1193.
10. Holm T., Andreassen A.K., Ueland T., Kjekshus J., Froland S.S., Kjekshus E., Simonsen S., Aukrust P., Gullestad L. Effect of pravastatin on plasma markers of inflammation and peripheral endothelial function in male heart transplant recipients. Am J Cardiol. 87:2001;815-818.
11. Palinski W., Tsimikas S. Immunomodulatory effects of statins mechanisms and potential impact on arteriosclerosis. J Am Soc Nephrol. 13:2002;1673-1681.
12. Node K., Fujita M., Kitakaze M., Hori M., Liao J.K. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation. 108:2003;839-843.
13. Kapadia S., Dibbs Z., Kurrelmeyer K., Kalra D., Seta Y., Wang F., Bozkurt B., Oral H., Sivasubramanian N., Mann D.L. The role of cytokines in the failing human heart. Cardiol Clin. 16:1998;645-656.
14. Blum A., Miller H. Pathophysiological role of cytokines in congestive heart failure. Annu Rev Med. 52:2001;15-27.
15. Packer M., O'Connor C.M., Ghali J.K., Pressler M.L., Carson P.E., Belkin R.N., Miller A.B., Neuberg G.W., Frid D., Wertheimer J.H., Cropp A.B., DeMets D.L. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. PRAISE Study Group. N Engl J Med. 335:1996;1107-1114.
16. O'Connor C.M., Carson P.E., Miller A.B., Pressler M.L., Belkin R.N., Neuberg G.W., Frid D.J., Cropp A.B., Anderson S., Wertheimer J.H., DeMets D.L. Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE trial. Am J Cardiol. 82:1998;881-887.
17. Jones P., Kafonek S., Laurora I., Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 81:1998;582-587.
18. Rosenbaum P.R., Rubin D.B. The central role of the propensity score in observational studies for causal effects. Biometrika. 70:1983;41-55.
19. Horwich T.B., Hamilton M.A., Maclellan W.R., Fonarow G.C. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail. 8:2002;216-224.
20. Mitchell L.B., Powell J.L., Gillis A.M., Kehl V., Hallstrom A.P., AVID Investigators. Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmics versus Implantable Defibrillators (AVID) trial. J Am Coll Cardiol. 42:2003;81-87.
21. Tracy R.P., Psaty B.M., Macy E., Bovill E.G., Cushman M., Cornell E.S., Kuller L.H. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol. 17:1997;2167-2176.
22. Bauersachs J., Galuppo P., Fraccarollo D., Christ M., Ertl G. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation. 104:2001;982-985.
23. Hayashidani S., Tsutsui H., Shiomi T., Suematsu N., Kinugawa S., Ide T., Wen J., Takeshita A. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation. 105:2002;868-873.
24. Pliquett R.U., Cornish K.G., Peuler J.D., Zucker I.H. Simvastatin normalizes autonomic neural control in experimental heart failure. Circulation. 107:2003;2493-2498.
25. Kjekshus J., Pedersen T.R., Olsson A.G., Faergeman O., Pyorala K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail. 3:1997;249-254.